Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.30 |
| ▸ | JAK1 | P23458 | 3/20 | 0.30 |
| ▸ | TYK2 | P29597 | 3/20 | 0.30 |
| ▸ | JAK3 | P52333 | 3/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489406 | 0.93 | PIK3CG (0.42) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL31489451 | 0.89 | PIK3CD (0.37) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL31489510 | 0.89 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CBJAK2 | |
| SCHEMBL31489391 | 0.89 | PIK3CD (0.32) | PIK3CDPIK3CGPIK3CAJAK2JAK1 | |
| SCHEMBL31489891 | 0.88 | PIK3CD (0.37) | PIK3CDPIK3CGPIK3CBJAK2 | |
| SCHEMBL31489547 | 0.87 | PIK3CD (0.36) | PIK3CDPIK3CGPIK3CB | |
| SCHEMBL31489514 | 0.86 | — | — | |
| SCHEMBL31489356 | 0.84 | PIK3CG (0.40) | PIK3CDPIK3CGPIK3CBPIK3CAJAK1 | |
| SCHEMBL31489880 | 0.81 | PIK3CG (0.42) | PIK3CDPIK3CGPIK3CB | |
| SCHEMBL31489766 | 0.81 | PIK3CD (0.33) | PIK3CDPIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |